Clearmind files European patent for new psychedelic compounds to treat PTSD, boosting its IP in a $30B market.

Clearmind Medicine Inc. has filed a European patent application for novel psychedelic compounds aimed at treating PTSD and other mental health disorders. This move strengthens Clearmind's intellectual property in Europe and aligns with recent U.S. policy encouraging psychedelic therapy research. The global PTSD treatment market is expected to grow to $30.2 billion by 2035, highlighting the commercial potential. Clearmind holds exclusive global rights to develop and commercialize these compounds under a licensing deal with Yissum Research Development Company.